UK: Keep Calm And Carry On: How Can The Healthcare And Life Sciences Industries Weather The Brexit Storm?

Last Updated: 11 July 2016
Article by Karen Taylor

We have now had the best part of a week to absorb the momentous news that the UK has voted to leave the European Union. Much has been written about this seismic event and, following our blog in February this year, on what Brexit might mean for the healthcare and life sciences industries,i we thought we should use this week's blog to update our views on the potential risks and opportunities for our life sciences and healthcare sectors.

What we know for certain is that the UK government faces the unprecedented task of engineering the UK's withdrawal from the EU, in the absence of any template or good practice model. We also expect that Brexit will not happen immediately nor indeed for at least another two years. For now, the UK can draw on its evident strengths, including the fact that it:

  • is in the top tier of the world's most competitive economies
  • has strong institutions and a highly skilled workforce
  • has enjoyed a great deal of success in attracting inward investment
  • has four of the world's top 20 universities (and the strongest global university rankings in Europe)
  • enjoys unemployment rates among the lowest in Europe, with employment at record levels demonstrating a level of economic resilience in the face of slower growth in much of the rest of the world.

In considering the likely risks to this position for the healthcare and life sciences industries, it is useful to examine the implications through a number of specific lenses: talent, regulation and investment and research funding.

Talent

Both health and life sciences companies are dependent on the mobility of skills across Europe, with over 10 per cent of doctors, four per cent of nurses and 15 per cent of academic staff in UK research institutions, from other EU countries.ii While the leave vote could eventually result in restrictions of the free movement of people in the EU, it may also deter other EU staff, with the requisite clinical and research skills, from choosing to work in the UK. While the above percentages may seem like a relatively small proportion of staff (in England this equate to some 55,000 out of 1.2 million NHS staff), a recent National Audit Office report highlights the fragility of the current staffing situation in the English NHS. Currently the gap between what providers say they need and the numbers in post is some 5.9 per cent (or around 50,000 full-time equivalents) with notable gaps in nursing, midwifery and health visitors.iii Losing the EU as a source of skilled staff could tip the balance in service delivery for the NHS. For our universities, there is a risk that Brexit could shift the balance of power in academic research away from the UK.

There are similar risks to the pharmaceutical labour force. Brexit could end up isolating the country's scientists and reducing its influence in medicine. Most research and development facilities in the UK include staff from across the EU and Brexit may mean pharmaceutical companies will find it more difficult to attract talent from abroad and retain existing talent. If EU funding was cut to UK research projects, academics may well desert the UK for countries with easier access to collaborative international research projects. Moreover, UK scientists, and pharmaceutical executives may no longer enjoy the same rights as they do now to work in any EU country.

Until the UK extracts itself from its obligations under EU treaties, the policy on freedom of movement remains unchanged, however, there is a need for the government to clarify at the earliest opportunity its intentions on the ability of EU nationals to work in the above roles in the UK, and to consider adding these occupations to the Migration Advisory Committee's shortage occupation list.iv 

Regulation

The UK's role and influence on the regulatory landscape in Europe is also likely to change now that the UK has voted to leave the EU. The European Medicines Agency (EMA) is likely to come under immediate pressure to consider moving its headquarters from London to another EU member state. Already countries like Denmark, with its vibrant life science industry, is offering to host the EMA. Furthermore, the close ties between the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and the EMA, that resulted from their close proximity, could be adversely affected and potentially lead to a decrease in influence over regulation and participation in assessment activity, including the assessment of new drugs. Conversely, Brexit could provide the UK with an opportunity to introduce a more collaborative regulatory regime.

Other issues that will impact the future of the life sciences industry include the fact that:

  • most drugs are approved for sale in EU countries by the EMA, giving drug-makers a single marketing authorisation, the UK may have to resume separate authorisations and inspections
  • cutting ties with the EMA could impact where pharmaceutical companies choose to run their clinical trials, the current mutual recognition and central drug approval pathway can provide faster access to Europe's half a billion potential patients (avoiding the need to navigate multiple national drug approval pathways)v
  • the new EU Clinical Trials Regulation (CTR), whose provisions are due to take effect in late 2018, offers the possibility of a single trial application for multicentre clinical trials, and a new database that will make it easier to access trial data. If outside the EU, the UK may not be able to access these systems.

Investment and research funding

Membership of the EU has been important in attracting investment into domestic life science capabilities, Brexit is likely to result in the following risks to such investments:

  • global pharmaceutical companies invest in the UK to sell to the domestic and other EU markets, Brexit risks removing this incentive
  • UK universities receives more funding from the European Research Council than any other EU country, Brexit threatens the receipt of this (some Euros 8.5 billion for UK science over the next four years).vi There is also a risk that UK researchers will lose their priority access to scientific facilities across Europevii
  • a wide range of EU public/private partnerships exist, like the Innovative Medicines Initiative (IMI), while half of the funding for the IMI comes from the EU, the advantages lie not just in the money but in the ability to bring together companies and researchers from different EU countries. Domestic research investment is likely to suffer if the UK was no longer part of this initiative.

The life sciences industry is a critical element of the UK economy, accounting for over 220,000 jobs and revenue of over £60 billion, according to the Office of Life Science.viii The UK has a strong history of research and commercial science, having pioneered many scientific breakthroughs and driven scientific collaboration worldwide. The UK received Euro 8.8 billion in direct EU funding for research, development and innovation activities from 2007 to 2013, the second largest beneficiary of research funding of all European countries.ix While many commentators believe this funding could ultimately reduce or even disappear there is an opportunity to build on the government's Innovation Health and Wealth Strategy and Life Sciences strategy to maintain the UK's position as a leader in medical research.

The UK also plays an important role in initiatives like early-access programmes, adaptive pathways and international collaboration on health technology assessments. Brexit could jeopardize UK participation in pan-European projects intended to speed up patient access to innovation. However, the government's imminent publication of the Accelerated Access Review could provide a boost to the UKs position.

Conclusion

While we now know the results of the referendum we are still left with a great deal of uncertainty. What is likely is that there will be complex consequences for the healthcare and life sciences industries. As the many nuances become clearer, including whether the UK decides it wants to be part of the European Economic Area (EEA), join the European Free Trade Association, or negotiate a more remote trade relationship, there is likely to be a growing belief that like Switzerland's pharmaceuticals industry, life outside the EU can be compatible with a thriving life-sciences sector.

We believe that the UK is likely to remain a world leader in R&D and a hub for innovation. This will help businesses capitalise on the opportunities and respond to the competitive threats created by the Brexit storm vote. The government must also play an active role in setting a vision for a new, post-EU environment which is open, pro-growth and delivers prosperity and opportunity for all. The resilience and dynamism of our economy and institutions and the uniqueness offered by a resilient NHS, will be huge advantages as we start to navigate a prosperous future outside the EU.

Footnotes

i http://blogs.deloitte.co.uk/health/2016/02/what-would-brexit-mean-for-the-pharma-industry.html
ii https://fullfact.org/immigration/immigration-and-nhs-staff/
iii https://www.nao.org.uk/report/managing-the-supply-of-nhs-clinical-staff-in-england/
iv https://www.gov.uk/government/organisations/migration-advisory-committee
v  http://uk.reuters.com/article/us-britain-eu-medicines-idUKKCN0V71AS
vi http://www.ft.com/cms/s/0/9216298e-bf67-11e5-846f-79b0e3d20eaf.html#axzz3zr7WOYXF
vii http://www.nature.com/news/academics-across-europe-join-brexit-debate-1.19282
viii https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/525102/bis-16-237-strength-and-opportunity-2015-UK-medical-and-biopharmaceutical-landscape.pdf
ix https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.